Ex-Merck Guy To Clear Path, For Ex-Abbott Guy — At Vertex

This is a much tighter circle than the first-glance “six degrees of Kevin Baconusual game might otherwise suggest, here — especially given that Vertex’s closest current competitor is Merck itself (well, okay — technically, it’s legacy Schering-Plough, but you know what I mean). [See, Incivek® posts here.]

Here is more, per this morning’s Boston Herald — do go read it all, there — this is a bit of it:

. . . .The front-office shuffle comes as the Cambridge-based company — now building a massive new waterfront headquarters in Boston’s Seaport District — prepares to bring its second drug to market. The Food and Drug Administration has agreed to expedite its review of the first potential treatment targeting the underlying cause of cystic fibrosis.

A board member since 2009, Leiden is a managing director at Clarus Ventures in Cambridge. He previously was president of Abbott Laboratories and has experience as a practicing cardiologist. . . .

Indeed. I still think Vertex has been oversold by Wall Street — it has a clear path (leading the Hep C next-gen state of the art) until at least 2015, in my estimation.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s